E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders. |
|
E.1.1.1 | Medical condition in easily understood language |
Parkinson's disease patients with associated movement and sleep disorders. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061536 |
E.1.2 | Term | Parkinson's disease |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate in an exploratory manner the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson’s disease (PD) patients with end-of-dose motor fluctuations and associated sleep disorders. |
|
E.2.2 | Secondary objectives of the trial |
1. To investigate in an exploratory manner the efficacy of opicapone 50 mg in reducing further symptoms 2. To investigate the safety and tolerability of opicapone 50 mg once daily |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Able to comprehend and willing to sign an informed consent form and to comply with all aspects of the study. 2. Male or female patients aged 30 years or older. 3. Diagnosed with idiopathic PD according to the UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria (2006) or according to MDS Clinical Diagnostic Criteria (2015). 4. Signs of “wearing-off” phenomenon (end-of-dose motor fluctuations) with average total daily OFF time while awake of at least 1.5 hours, excluding the early morning pre-first dose OFF, despite optimal anti-PD therapy (based on investigator’s assessment). 5. Disease severity Stages I-III (modified Hoehn & Yahr staging) at ON. 6. Experiencing PD associated sleep disorders for at least 4 weeks prior to V1. 7. Total PDSS-2 score ≥ 18. 8. Treated with 3 to 8 intakes per day of L-dopa/DDCI (which may include a slow-release formulation), on a stable regimen for at least 4 weeks before V1. 9. In case of any other anti-PD treatment, it should be on a stable regimen for at least 4 weeks before V1, and not likely to need any adjustment until V4. 10. No change in the chronic treatment regimen within the last 4 weeks before V1 of the following medication: sedatives, hypnotics, anti-depressants, anxiolytics or other medications prescribed for the treatment of sleep disorders 11. For females: Postmenopausal for at least 2 years before V1, surgically sterile for at least 6 months before V1, or practicing an effective method of contraception until V4. Female patients who request to continue with oral contraceptives must be willing to use non-hormonal methods of contraception in addition during the course of this study. For males: Male patients who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception during the treatment period until V4. 12. Have filled-in self-rating diary in accordance with the diary instructions and with ≤ 3 errors per day when awake, in the 3 days preceding V2a/V2b. 13. With at least 1.5 OFF hours per day, excluding the early morning pre-first dose OFF period (i.e. the time between wake-up and response to the first L-dopa/DDCI dosage), as recorded in at least 2 of the 3 days in the self-rating diary for the 3 days preceding V2a/V2b. 14. Total PDSS-2 score ≥ 18. 15. Adequate compliance to relevant (PD and sleep disorders) concomitant medication during the screening period (based on the investigator’s judgment). |
|
E.4 | Principal exclusion criteria |
1. Non-idiopathic PD (atypical parkinsonism, secondary [acquired or symptomatic] parkinsonism, Parkinson-plus syndrome). 2. Severe and/or unpredictable OFF periods, according to investigator judgement. 3. Major/prominent non-PD-related sleep disorders (e.g. sleep apnoea or narcolepsy). 4. Treatment with prohibited medication: entacapone, tolcapone, monoamine oxidase (MAO) inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation, rasagiline up to 1 mg/day or safinamide up to 100 mg/day), or antiemetics with antidopaminergic action (except domperidone) within the last 4 weeks before V1 or likely to be needed at any time until V4. 5. Treatment with apomorphine within the last 4 weeks before V1 or likely to be needed at any time until V4. 6. Previous or current use of opicapone. 7. Previous or planned (until the end of this study) L-dopa/carbidopa intestinal gel infusion, deep brain stimulation or stereotactic surgery (e.g. pallidotomy, thalamotomy). 8. Use of any other investigational product (IP), currently or within the 3 months (or within 5 half-lives of the IP, whichever is longer) before V1. 9. Past (within the past year) or present history of suicidal ideation or suicide attempts. 10. Current or previous (within the past year) alcohol or substance abuse excluding caffeine or nicotine. 11. Phaeochromocytoma, paraganglioma, or other catecholamine secreting neoplasms. 12. Known hypersensitivity to the excipients of IP (including lactose intolerance, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption). 13. History of neuroleptic malignant syndrome or non-traumatic rhabdomyolysis. 14. History of severe hepatic impairment (Child-Pugh Class C). 15. Previous history of psychosis or psychiatric disorders, including severe major depression. 16. Any medical condition that might place the patient at increased risk or interfere with assessments. 17. For females: Pregnant or breastfeeding. 18. Employees of the investigator, study centre, sponsor, clinical research organisation and study consultants, when employees are directly involved in this study or other studies under the direction of this investigator or study centre, and their family members. 19. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Total score of Parkinson’s Disease Sleep Scale – version 2 (PDSS-2) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Change from baseline in Parkinson’s Disease Fatigue Scale (PFS-16) 2. Change from baseline in Domain K (sleep and wakefulness) of Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS) 3. Change from baseline in total score of MDS-NMS 4. Change from baseline in Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III and IV 5. Change from baseline in Parkinson’s Disease Questionnaire-8 (PDQ-8) 6. Clinical Global Impression of Change (CGIC) 7. Patient’s Global Impression of Change (PGIC) 8. Change from baseline in functional status via Hauser’s PD diary 9. Change from baseline in quality of sleep 10. Changes from baseline in morning dystonia 11. Incidence of adverse events (AEs) including serious AEs (SAEs) 12. Changes from baseline in vital signs 13. Changes from baseline in physical and neurological examinations |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |